Part I: Description of consignment

I.1. Consignor
Name
Address
Country ISO Code

I.2. IMSOC reference

I.2.a. Local reference

I.3. Central Competent Authority

I.4. Local Competent Authority

I.5. Consignee
Name
Address
Country ISO Code

I.6. Operator conducting assembly operations independently of an establishment
Name
Address
Approval Number
Country ISO Code

I.7. Country of origin ISO Code

I.9. Country of destination ISO Code

I.8. Region of origin Code

I.10. Region of destination Code

I.11. Place of dispatch
Name
Address
Approval Number
Country ISO Code

I.12. Place of destination
Name
Address
Approval Number
Country ISO Code

I.13. Place of loading
Name
Address
Approval Number
Country ISO Code

I.14. Date and time of departure

I.15. Means of Transport

Mode	International transport document	Identification

I.16. Transporter
Name
Address
Activity ID
Country ISO Code

I.17. Accompanying documents
Commercial document reference
Date of issue
Country
Place of issue

I.18. Transport conditions
Frozen ☐ Chilled ☐ Ambient ☐

I.19. Container No / Seal No

I.20. Certified as
Germinal products ☐

I.21. For transit through a third country ☐
Third country ISO Code
Exit point BCP code
Entry point BCP code

I.22. For transit through Member State(s) ☐
Member State ISO Code

I.23. For export ☐
Third country ISO Code
Exit point BCP code

I.25. Journey Log

I.26. Total number of packages

I.27. Total quantity

I.28. Total gross weight

I.30. Description of consignment

Commodity	Species	Identification Number	Quantity	Nature of commodity

Identification Mark	Package count	Date of collection / production	Plant / Establishment / Centre	Type

Part II: Certification

II. Health information

I, the undersigned official veterinarian, hereby certify that:

(1) ○ either [II.1. the in vivo derived embryos/in vivo derived ova(1) described in Part I were collected, processed and stored by an embryo collection team(2) approved and supervised in accordance with Chapter I(III)(1) of Annex D to Directive 92/65/EEC(3);]

(1) ○ or [II.1. the in vitro produced embryos/micromanipulated embryos(1) described in Part I were produced, processed and stored by an embryo production team(2), approved and supervised in accordance with Chapter I(III) (1) and (2) of Annex D to Directive 92/65/EEC;]

(1) ○ either [II.2. the in vivo derived embryos described in Part I meet the requirements of Chapter III(II)(1) of Annex D to Directive 92/65/EEC;]

(1) ○ or [II.2. the in vivo derived ova described in Part I meet the requirements of Chapter III(II)(2) of Annex D to Directive 92/65/EEC;]

(1) ○ or [II.2. the in vitro produced embryos described in Part I meet the requirements of Chapter III(II)(3) of Annex D to Directive 92/65/EEC;]

(1) ○ or [II.2. the micromanipulated embryos described in Part I meet the requirements of Chapter III(II)(4) of Annex D to Directive 92/65/EEC;]

II.3. the ova or embryos described in Part I come from donor mares which:

II.3.1. come from holdings fulfilling the conditions laid down in Article 4(5) of Directive 2009/156/EC(4) onto which only equidae satisfying the conditions laid down in Articles 4 and 5 or Articles 12 to 16 of Directive 2009/156/EC were admitted;

II.3.2. meet the requirements of Chapter IV(4) of Annex D to Directive 92/65/EEC;

II.3.3. were not used for natural breeding during a period of at least 30 days prior to the date of collection of the ova or embryos and between the date of the first sample referred to in points II.3.4.1 and II.3.4.2. and the date of the collection of the ova or embryos;

II.3.4. underwent the tests, which meet at least the requirements of the relevant Chapter of the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals of the OIE, carried out in a laboratory which is recognised by the competent authority and has the tests referred to hereinafter included in its accreditation in accordance with Article 12 of Regulation (EC) No 882/2004(5), as follows:

II.3.4.1. for equine infectious anaemia (EIA), an agar-gel immuno-diffusion test (AGID or Coggins test) or an enzyme-linked immunosorbent assay (ELISA) with a negative result carried out on a blood samples taken on (6), being not less than 14 days following the date of commencement of the period referred to in point II.3.3, and the test was last carried out on a sample of blood taken on (6); being not more than 90 days prior to the date of the collection of the ova or embryos intended for trade;

II.3.4.2. for contagious equine metritis (CEM), an agent identification test carried out with a negative result on at least two specimens (swabs) taken during the period referred to in point II.3.3 from at least the mucosal surfaces of the clitoral fossa and the clitoral sinuses of the donor mare;

(1) ☐ either [II.3.4.2.1. on two occasions with an interval of not less than 7 days on (6) and on (6), in the case of isolation of Taylorella equigenitalis after cultivation under microaerophilic conditions for a period of at least 7 days, set up within the 24 hour period after taking the specimens from the donor animal, or the 48 hour period where the specimens are kept cool during transport;]

(1) ☐ and/or [II.3.4.2.2. on one occasion on (6), in the case of the detection of genome of Taylorella equigenitalis by a polymerase chain reaction (PCR) or real-time PCR test, carried out within the 48 hour period after taking the specimens from the donor animal.]

Part II: Certification

II. Health information

The samples referred to in points II.3.4.2.1. and II.3.4.2.2. were in no case taken earlier than 7 days (systemic treatment) or 21 days (local treatment) after antimicrobial treatment of the donor mare and were placed in transport medium with activated charcoal, such as Amies medium, before dispatch to the laboratory;

(1) ○ either [II.4. the embryos described in Part I were conceived as a result of artificial insemination of the donor mares with semen which was collected, processed, stored and transported under conditions which comply with the requirements of Chapters I(I), II(I) and III(I) of Annex D to Directive 92/65/EEC;]

(1) ○ or [II.4. the embryos described in Part I were conceived as a result of in vitro fertilisation of ova complying with the conditions set out in point 2 of Chapter III(II) of Annex D to Directive 92/65/EEC with semen which was collected, processed, stored and transported under conditions which comply with the requirements of Chapters I(I), II(I) and III(I) of Annex D to Directive 92/65/EEC;]

(1) ○ or [II.4. the ova have not been in contact with semen of the equine species;]

II.5. the ova or embryos described in Part I were sent to the place of loading in a sealed container in accordance with point 6 of Chapter III(II) of Annex D to Directive 92/65/EEC and bearing the number detailed in Box I.19.

Notes

This animal health certificate shall be completed according to the notes for the completion of certificates provided for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.

Part I:

Box I.11: The place of dispatch shall correspond to the embryo collection team or embryo production team of ova/embryos collection/production.

Box I.12: The place of destination shall correspond to the embryo collection team, embryo production team or to the holding of ova/embryos destination.

Box I.19: The identification of container and Seal number shall be indicated.

Box I.30: “Type”: specify if: in vivo derived embryos, in vivo derived oocytes, in vitro produced embryos or micromanipulated embryos.

The donor identity shall correspond to the official identification of the animal.

The date of collection shall be indicated in the following format: dd/mm/yyyy.

Part II:

(1) Delete as appropriate.

(2) Only embryo collection or production teams approved by the competent authority and listed in accordance with Article 11(4) of Directive 92/65/EEC.

(3) OJ L 268, 14.9.1992, p. 54.

(4) OJ L 192, 23.7.2010, p. 1.

(5) OJ L 165, 30.4.2004, p. 1.

(6) Insert date.

Certifying Officer/Official veterinarian

Name (in capital letters) Authority name

Date of signature Signature

Stamp